|Bid||84.55 x 900|
|Ask||84.22 x 900|
|Day's Range||84.13 - 86.79|
|52 Week Range||62.55 - 101.28|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||18.64|
|Earnings Date||Oct 30, 2020|
|Forward Dividend & Yield||4.72 (5.47%)|
|Ex-Dividend Date||Oct 14, 2020|
|1y Target Est||109.12|
Already given the green light for rheumatoid arthritis, the drug could soon be prescribed for a common skin ailment.
AbbVie (NYSE: ABBV) today announced that it has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for RINVOQ™ (upadacitinib) for the treatment of adults (15 mg and 30 mg, once daily) and adolescents (15 mg, once daily) with moderate to severe atopic dermatitis.
Roche (RHHBY) and partner AbbVie obtain full FDA approval for leukemia drug, Venclexta, in combination with Vidaza or Dacogen or low-dose cytarabine (LDAC).